Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Mar;71(3):451–455. doi: 10.1038/bjc.1995.92

A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma.

N J McKenna 1, D G Kieback 1, D N Carney 1, M Fanning 1, J McLinden 1, D R Headon 1
PMCID: PMC2033643  PMID: 7880723

Abstract

Clinical outcome in ovarian carcinoma is predicted by progesterone receptor status, indicating an endocrine aspect to this disease. Peripheral leucocyte genomic DNAs were obtained from 41 patients with primary ovarian carcinoma and 83 controls from Ireland, as well as from 26 primary ovarian carcinoma patients and 101 controls in Germany. Southern analysis using a human progesterone receptor (hPR) cDNA probe identified a germline TaqI restriction fragment length polymorphism (RFLP) defined by two alleles: T1, represented by a 2.7 kb fragment; and T2, represented by a 1.9 kb fragment and characterised by an additional TaqI restriction site with respect to T1. An over-representation of T2 in ovarian cancer patients compared with controls in the pooled Irish/German population (P < 0.025) was observed. A difference (P < 0.02) in the distribution of the RFLP genotypes between Irish and German control populations was also observed. The allele distributions could not be shown to differ significantly from Hardy-Weinberg distribution in any subgroup. Using hPR cDNA region-specific probes, the extra TaqI restriction site was mapped to intron G of the hPR gene.

Full text

PDF
451

Images in this article

453Figure 2
on p.453
453Figure 3
on p.453
453Figure 4
on p.453

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chadha S., Rao B. R., Slotman B. J., van Vroonhoven C. C., van der Kwast T. H. An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum Pathol. 1993 Jan;24(1):90–95. doi: 10.1016/0046-8177(93)90067-q. [DOI] [PubMed] [Google Scholar]
  2. Dobson A. D., Conneely O. M., Beattie W., Maxwell B. L., Mak P., Tsai M. J., Schrader W. T., O'Malley B. W. Mutational analysis of the chicken progesterone receptor. J Biol Chem. 1989 Mar 5;264(7):4207–4211. [PubMed] [Google Scholar]
  3. Foulkes W. D., Campbell I. G., Stamp G. W., Trowsdale J. Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer. Br J Cancer. 1993 Feb;67(2):268–273. doi: 10.1038/bjc.1993.51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fuqua S. A., Hill S. M., Chamness G. C., Benedix M. G., Greene G. L., O'Malley B. W., McGuire W. L. Progesterone receptor gene restriction fragment length polymorphisms in human breast tumors. J Natl Cancer Inst. 1991 Aug 21;83(16):1157–1160. doi: 10.1093/jnci/83.16.1157. [DOI] [PubMed] [Google Scholar]
  5. Hampton G. M., Penny L. A., Baergen R. N., Larson A., Brewer C., Liao S., Busby-Earle R. M., Williams A. W., Steel C. M., Bird C. C. Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6953–6957. doi: 10.1073/pnas.91.15.6953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  7. Kastner P., Krust A., Turcotte B., Stropp U., Tora L., Gronemeyer H., Chambon P. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 1990 May;9(5):1603–1614. doi: 10.1002/j.1460-2075.1990.tb08280.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kieback D. G., Runnebaum I. B., Moebus V. J., Kreienberg R., McCamant S. K., Edwards C. L., Jones L. A., Tsai M. J., O'Malley B. W. Chicken ovalbumin upstream promoter transcription factor (COUP-TF): an orphan steroid receptor with a specific pattern of differential expression in human ovarian cancer cell lines. Gynecol Oncol. 1993 Nov;51(2):167–170. doi: 10.1006/gyno.1993.1266. [DOI] [PubMed] [Google Scholar]
  9. Knudson A. G., Jr Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971 Apr;68(4):820–823. doi: 10.1073/pnas.68.4.820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Mattei M. G., Krust A., Stropp U., Mattei J. F., Chambon P. Assignment of the human progesterone receptor to the q22 band of chromosome 11. Hum Genet. 1988 Jan;78(1):96–97. doi: 10.1007/BF00291245. [DOI] [PubMed] [Google Scholar]
  11. Misrahi M., Atger M., d'Auriol L., Loosfelt H., Meriel C., Fridlansky F., Guiochon-Mantel A., Galibert F., Milgrom E. Complete amino acid sequence of the human progesterone receptor deduced from cloned cDNA. Biochem Biophys Res Commun. 1987 Mar 13;143(2):740–748. doi: 10.1016/0006-291x(87)91416-1. [DOI] [PubMed] [Google Scholar]
  12. Misrahi M., Venencie P. Y., Saugier-Veber P., Sar S., Dessen P., Milgrom E. Structure of the human progesterone receptor gene. Biochim Biophys Acta. 1993 Nov 16;1216(2):289–292. doi: 10.1016/0167-4781(93)90156-8. [DOI] [PubMed] [Google Scholar]
  13. Noguchi T., Kitawaki J., Tamura T., Kim T., Kanno H., Yamamoto T., Okada H. Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women. J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):657–660. doi: 10.1016/0960-0760(93)90275-2. [DOI] [PubMed] [Google Scholar]
  14. Rousseau-Merck M. F., Misrahi M., Loosfelt H., Milgrom E., Berger R. Localization of the human progesterone receptor gene to chromosome 11q22-q23. Hum Genet. 1987 Nov;77(3):280–282. doi: 10.1007/BF00284486. [DOI] [PubMed] [Google Scholar]
  15. Sandy M. S., Chiocca S. M., Cerutti P. A. Genotypic analysis of mutations in Taq I restriction recognition sites by restriction fragment length polymorphism/polymerase chain reaction. Proc Natl Acad Sci U S A. 1992 Feb 1;89(3):890–894. doi: 10.1073/pnas.89.3.890. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Slotman B. J., Nauta J. J., Rao B. R. Survival of patients with ovarian cancer. Apart from stage and grade, tumor progesterone receptor content is a prognostic indicator. Cancer. 1990 Aug 15;66(4):740–744. doi: 10.1002/1097-0142(19900815)66:4<740::aid-cncr2820660423>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  17. Wanless C., Barker S., Puddefoot J. R., Panahy C., Goode A. W., Vinson G. P., Phillips I. R. Somatic change in the estrogen receptor gene associated with altered expression of the progesterone receptor. Anticancer Res. 1991 Jan-Feb;11(1):139–142. [PubMed] [Google Scholar]
  18. Yaich L., Dupont W. D., Cavener D. R., Parl F. F. Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. Cancer Res. 1992 Jan 1;52(1):77–83. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES